Table 3 Relationship between immunochemical features and tumor grade
From: Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
Target expression | Low-grade, % | High-grade, % | p-value | Target expression | Low-grade, % | High-grade, % | p-value |
|---|---|---|---|---|---|---|---|
VEGFA | Â | Â | Â | APOE | Â | Â | Â |
1 | 4 (16.7%) | 43 (30.9%) | 0.031 | 1 | 6 (25.0%) | 24 (14.7%) | 0.598 |
2 | 3 (12.5%) | 40 (28.8%) | Â | 2 | 5 (20.8%) | 39 (23.9%) | Â |
3 | 7 (29.2%) | 30 (21.6%) | Â | 3 | 5 (20.8%) | 46 (28.2%) | Â |
4 | 10 (41.7%) | 26 (18.7%) | Â | 4 | 8 (33.3%) | 54 (33.1%) | Â |
MMP9 | Â | Â | Â | SERPINA1 | Â | Â | Â |
1 | 3 (12.5%) | 10 (6.5%) | 0.161 | 1 | 2 (9.1%) | 32 (20.4%) | 0.021 |
2 | 9 (37.5%) | 36 (23.5%) | Â | 2 | 10 (45.5%) | 27 (17.2%) | Â |
3 | 8 (33.3%) | 50 (32.7%) | Â | 3 | 5 (22.7%) | 43 (27.4%) | Â |
4 | 4 (16.7%) | 57 (37.3%) | Â | 4 | 5 (22.7%) | 55 (35.0%) | Â |
MMP10 | Â | Â | Â | SDC1 | Â | Â | Â |
1 | 7 (29.2%) | 29 (19.0%) | 0.611 | 1 | 2 (8.0%) | 25 (15.7%) | 0.222 |
2 | 3 (12.5%) | 32 (20.9%) | Â | 2 | 3 (12.0%) | 31 (19.5%) | Â |
3 | 6 (25.0%) | 39 (25.5%) | Â | 3 | 7 (28.0%) | 53 (33.3%) | Â |
4 | 8 (33.3%) | 53 (34.6%) | Â | 4 | 13 (52.0%) | 50 (31.4%) | Â |
SERPINE1 | Â | Â | Â | ANG | Â | Â | Â |
1 | 10 (41.7%) | 34 (22.4%) | 0.213 | 1 | 0 (0%) | 4 (2.5%) | 0.783 |
2 | 4 (16.7%) | 27 (17.8%) | Â | 2 | 7 (29.2%) | 47 (28.8%) | Â |
3 | 5 (20.8%) | 38 (25.0%) | Â | 3 | 7 (29.2%) | 56 (34.4%) | Â |
4 | 5 (20.8%) | 53 (34.9%) | Â | 4 | 10 (41.7%) | 56 (34.4%) | Â |
IL8 | Â | Â | Â | Â | Â | Â | Â |
1 | 9 (37.5%) | 43 (26.2%) | 0.699 | Â | Â | Â | Â |
2 | 4 (16.7%) | 37 (22.6%) | Â | Â | Â | Â | Â |
3 | 4 (16.7%) | 32 (19.5%) | Â | Â | Â | Â | Â |
4 | 7 (29.2%) | 52 (31.7%) | Â | Â | Â | Â | Â |
CA9 | Â | Â | Â | Â | Â | Â | Â |
1 | 7 (30.4%) | 28 (16.9%) | 0.206 | Â | Â | Â | Â |
2 | 6 (26.1%) | 40 (24.1%) | Â | Â | Â | Â | Â |
3 | 2 (8.7%) | 43 (25.9%) | Â | Â | Â | Â | Â |
4 | 8 (34.8%) | 55 (33.1%) | Â | Â | Â | Â | Â |